Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201303150 Principal Investigator: Tan, Benjamin
Title: A phase I/II study of X-82, an oral anti-VEGFR tyrosine kinase inhibitor, with everolimus for patients with pancreatic neuroendocrine tumors
Description: The purpose of this research study is to determine the best dose of a drug called X-82 when it is combined with everolimus, as well as to look at side effects that may occur when people receive this combination of drugs....MORE
___________________________________________________________________________________________________
 Number: 201210123 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study Combining MLN8237 with nab-Paclitaxel in Patients with Advanced Solid Malignancies
Description: The purpose of this research study is to discover the appropriate dose of the drugs MLN8237 and nab-paclitaxel when they are given together, as well as to look at any side effects that might occur and to evaluate how these drugs work together in patients with cancer....MORE
___________________________________________________________________________________________________
 Number: 201108327 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE
___________________________________________________________________________________________________
 Number: 201304130 Principal Investigator: Lockhart, A. Craig
Title: A Phase 1B, Open-Label, Dose-Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel, in Patients with Solid Tumors
Description: The main purposes of this research study are to determine: • The discomforts and risks of MLN4924 in combination with docetaxel, paclitaxel and carboplatin, or gemcitabine • The highest dose of MLN4924 in combination with other standard treatments that can be given to patients without causing dis...MORE
___________________________________________________________________________________________________
 Number: 201210037 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I safety study of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies
Description: The purpose of this research study is to learn whether the use of Clostridium-novyi-NT in people with your type of cancer is safe and effective. Clostridium novyi-NT spores are bacteria. In laboratory animals, Clostridium novyi-NT spores can grow within tumors and destroy a large part of the tumors....MORE
___________________________________________________________________________________________________
 Number: 201204116 Principal Investigator: Lockhart, A. Craig
Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers
Description: The purpose of this research study is to learn whether a drug called vemurafenib is safe and effective in cancers caused by problems with the BRAF gene. Previous studies have shown that vemurafenib therapy can be beneficial in patients with a special type of metastatic melanoma that is caused by pro...MORE
___________________________________________________________________________________________________
 Number: 201107068 Principal Investigator: Lockhart, A. Craig
Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment
Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE
___________________________________________________________________________________________________
 Number: 201104365 Principal Investigator: Lockhart, A. Craig
Title: An open label, non-randomized Phase I study of regorafenib (BAY 73-4506) to evaluate cardiovascular safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors
Description: The purpose of this study is to find the answers to the following research questions: 1. Are there any side effects to your heart when taking the study drug (BAY 73-4506) that have not yet been seen in other studies using BAY 73-4506? 2. What are the other side effects of BAY 73-4506 when you take...MORE
___________________________________________________________________________________________________
 Number: 201104354 Principal Investigator: Govindan, Ramaswamy
Title: A Phase 1 study of BAY 80-6946 (phosphatidylinositol 3 - kinase inhibitor) in combination with paclitaxel in subjects with advanced solid malignancy
Description: The purpose of this study is to find the highest and safest dose of an investigational drug called BAY 80-6946 in combination with paclitaxel, determine the side effects of a weekly dosing, determine how much BAY 80-6946 is in the blood at specific times after administration, determine if this comb...MORE
___________________________________________________________________________________________________